Join members of the Yale and Harvard Law Schools on February 23 for the third installment of the COVID-19 and the Law: Disruption, Impact, and Legacy Seminar Series. Registration is required.
This seminar series will consider the ethical, legal, regulatory, and broader social and institutional impacts that COVID-19 has had, as well as the longer-lasting effects it may have on our society. This third seminar in the series will focus on the use of biotech in the COVID-19 pandemic.
The COVID-19 pandemic has affected almost all aspects of life in the United States and around the world, disrupting the global economy as well as countless institutions. The issues raised by the COVID-19 pandemic present a critical juncture for the U.S. and other countries around the world. Our actions now have the potential to shape responses to future pandemics, and to ensure institutions serve all of our populations.
How have our institutions, including the structure of our health care system and its attendant regulations, affected the evolution of the pandemic? What lasting changes have legal responses to COVID-19 introduced? Which institutions and intersectional issues have worsened or complicated the impact of and response to the pandemic? Join us for a critical reflection on changes the pandemic has introduced and their anticipated legacy.
PANELISTS:
- Introduction and Moderator: I. Glenn Cohen, James A. Attwood and Leslie Williams Professor of Law, Deputy Dean, and Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School
- Rachel Sachs, Associate Professor of Law, Washington University in St. Louis School of Law
- Katharine Van Tassel, Visiting Professor of Law, The Law-Medicine Center, Case Western Reserve University School of Law
- Govind Persad, Assistant Professor, Sturm College of Law
- Michael Sinha, Research Fellow, Harvard-MIT Center for Regulatory Science
Cosponsored by the Solomon Center for Health Law and Policy at Yale Law School, and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.